Celladon Corp., a San Diego-based biotech company, has announced the closing of its underwritten public offering of 4,600,000 shares of its common stock at $9.50 per share.

The public offering included 600,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $43.7 million before deducting underwriting discounts and commissions and other offering expenses payable by Celladon (Nasdaq: CLDN).

Credit Suisse and Jefferies LLC acted as joint book-running managers for the offering and Stifel and Wedbush PacGrow Life Sciences acted as co-managers.

In June, Celladon announced the appointment of industry veteran Paul Cleveland as its new president and chief financial officer.